ArticleBMC ophthalmology2025
Causes and prognosis of neovascular glaucoma after pars plana vitrectomy in patients with diabetic retinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02399887, which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Who cites it
3 citing papers in PubMed.
- Construction and Validation of a Long-Term Visual Prognosis Prediction Model for Proliferative Diabetic Retinopathy After Vitrectomy Based on Machine Learning.Endocrinology, diabetes & metabolism · 2026Article
- Adjuvant Anti-VEGF in Vitrectomy for Proliferative Diabetic Retinopathy: Current Evidence, Timing Considerations, and Clinical Implications.Current ophthalmology reports · 2026Article
- Association of vitreous CREG1 with diabetic macular edema response and edema resolution following ranibizumab therapy.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate factors and prognosis of neovascular glaucoma (NVG) after pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR).
methodsA total of 200 PDR patients with 225 eyes from May 2017 to January 2023 were retrospectively analyzed, including 115 males (128 eyes) and 85 females (97 eyes) with ages ranging from 30 to 75 years. All 25G PPV surgeries were completed by the same experienced chief physician. During the surgery, the anterior retinal fibrous vascular membrane was fully removed, and laser panretinal photocoagulation (PRP) was performed, phacoemulsification was combined in 114 patients. The average postoperative follow-up time was 10.65 ± 6.84 months and occurrence of NVG was recorded. Potential risk factors of NVG included age, glycated hemoglobin (HbAlc), blood urea nitrogen (BUN), severity of preoperative fundus lesion, preoperative treatment of anti-vascular endothelial growth factor (VEGF), preoperative PRP application, combination of phacoemulsification.
resultsAmong the total 225 eyes, 15 (6.7%) eyes developed NVG 1-12 months after surgery, including 11 cases within 6 months. Incidence of NVG was associated with age (t=-3.974), preoperative treatment of anti-VEGF (χ
conclusionsOccurrence of NVG in PDR was related to preoperative PRP and anti-VEGF, and might further have impact on prognosis. In addition, comprehensive consideration of patient's age, severity of preoperative fundus lesion and appropriate surgical method (i.e., whether combined with phacoemulsification) could be protective factors of NVG.
trial registrationClinicalTrials.gov, NCT02399887, Registered 25 March 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.